Michael C. Edler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael C. Edler has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Kaci Lacy
Department of Medical and Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA
2 shared publications- Birgit Kunert
Institute of Solid State Physics NAWI Graz Graz University of Technology Graz 8010 Austria
1 shared publication Casey Snoddy
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
1 shared publicationChris Hobbick
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
1 shared publicationClaire Wegel
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
1 shared publicationColleen M. Mitchell
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
1 shared publication
Latest Publications
- Open Access
- 16 September 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (9) , e70682
NCRAD: Advancing Alzheimer's research through high‐quality biospecimens and data
The National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) was established in 2002 to support research on the genetics of Alzheimer's disease. NCRAD quickly became a central resource, banking samples from numerous studies and distributing them to researchers worldwide. As genetic risk variants were identified, NCRAD prepared for functional studies by expanding its collections to include peripheral blood mononuclear cells (PBMCs), RNA, and biofluids. Over the past decade, NCRAD's extensive repository of plasma, serum, and cerebrospinal fluid was essential to the development of fluid biomarkers. NCRAD's rigorous best practices for sample collection, processing, and distribution ensure biospecimens are of the highest quality for a broad range of experimental approaches. Currently, NCRAD banks samples from 91 studies representing over 135,000 unique, well‐characterized participants, and has distributed over 440,000 aliquots to more than 300 researchers. Data from NCRAD‐supported studies have contributed to over 1100 publications and numerous key discoveries in Alzheimer's disease and related dementias (ADRD) genetics and biomarkers. Highlights: Centralized Biobanking for ADRD Research : National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) supports over 90 National Institute on Aging (NIA) ‐funded studies by providing standardized, high‐quality biospecimens and longitudinal sample collections, enabling reproducible and scalable research into Alzheimer's disease and related dementias (ADRD). Enabling Genetic Discovery and Functional Genomics : NCRAD partnerships with numerous research initiatives has facilitated major advances in gene discovery, while also supporting downstream functional studies using induced pluripotent stem cells (iPSCs), transcriptomics, and post mortem brain tissue. Rigorous QA/QC and Automation Infrastructure : NCRAD employs comprehensive quality assurance/quality control (QA/QC) systems and cutting‐edge automation—including robotic liquid handling, automated nucleic acid extraction, and ultra‐low temperature storage—to ensure biospecimen integrity and reduce preanalytical variability. Unique Sample Distribution and Data Sharing Model : NCRAD's blinded sample distribution system and emphasis on returning data to public repositories ensure broad research access, maximize scientific output, and promote transparency and reproducibility. Collaborative, Scalable Repository Ecosystem : As part of Indiana University's integrated biobanking infrastructure, NCRAD supports efficient cross‐study and cross‐repository research, enabling large‐scale multi‐omic and biomarker analyses across diverse neurodegenerative diseases.
- 16 September 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (9) , e70682
Open AccessNCRAD: Advancing Alzheimer's research through high‐quality biospecimens and data
The National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) was established in 2002 to support research on the genetics of Alzheimer's disease. NCRAD quickly became a central resource, banking samples from numerous studies and distributing them to researchers worldwide. As genetic risk variants were identified, NCRAD prepared for functional studies by expanding its collections to include peripheral blood mononuclear cells (PBMCs), RNA, and biofluids. Over the past decade, NCRAD's extensive repository of plasma, serum, and cerebrospinal fluid was essential to the development of fluid biomarkers. NCRAD's rigorous best practices for sample collection, processing, and distribution ensure biospecimens are of the highest quality for a broad range of experimental approaches. Currently, NCRAD banks samples from 91 studies representing over 135,000 unique, well‐characterized participants, and has distributed over 440,000 aliquots to more than 300 researchers. Data from NCRAD‐supported studies have contributed to over 1100 publications and numerous key discoveries in Alzheimer's disease and related dementias (ADRD) genetics and biomarkers. Highlights: Centralized Biobanking for ADRD Research : National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) supports over 90 National Institute on Aging (NIA) ‐funded studies by providing standardized, high‐quality biospecimens and longitudinal sample collections, enabling reproducible and scalable research into Alzheimer's disease and related dementias (ADRD). Enabling Genetic Discovery and Functional Genomics : NCRAD partnerships with numerous research initiatives has facilitated major advances in gene discovery, while also supporting downstream functional studies using induced pluripotent stem cells (iPSCs), transcriptomics, and post mortem brain tissue. Rigorous QA/QC and Automation Infrastructure : NCRAD employs comprehensive quality assurance/quality control (QA/QC) systems and cutting‐edge automation—including robotic liquid handling, automated nucleic acid extraction, and ultra‐low temperature storage—to ensure biospecimen integrity and reduce preanalytical variability. Unique Sample Distribution and Data Sharing Model : NCRAD's blinded sample distribution system and emphasis on returning data to public repositories ensure broad research access, maximize scientific output, and promote transparency and reproducibility. Collaborative, Scalable Repository Ecosystem : As part of Indiana University's integrated biobanking infrastructure, NCRAD supports efficient cross‐study and cross‐repository research, enabling large‐scale multi‐omic and biomarker analyses across diverse neurodegenerative diseases.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e091931
Neurodegeneration Focused Biorepositories: NCRAD, BioSEND, MJFF
Background: Biorepositories play an integral role in the advancement of our understanding of neurodegenerative diseases and improving human health outcomes. Research efforts are accelerated when access to high‐quality clinical specimens is made available from a large, diverse participant group. Indiana University is home to three important neurodegenerative disease‐focused biorepositories including the NIA‐funded National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), the NINDS‐funded Biospecimen Exchange for Neurological Disorders (BioSEND), and the Michael J. Fox Foundation (MJFF) biorepository. Having all three repositories in one location presents a unique opportunity to leverage common protocols and shared resources to provide researchers with access to a wide breadth of specimens, facilitating broad specimen sharing and standardization across studies and repositories.Method: All three repositories provide exceptional data and study coordination, data management, scientific support, and technical resources. Uniform best practice standard operating procedures (SOPs) and materials for collection and processing of samples yield consistently high‐quality specimens across studies from all repositories. Banked specimen types include DNA, RNA, whole blood, plasma, serum, cerebrospinal fluid, urine, stool, brain tissue, peripheral blood mononuclear cells (PBMCs), fibroblasts, and induced pluripotent stem cells (iPSCs). Online catalogs are available for specimen selection along with project management that can assist in the selection and approval of specimens across studies and repositories.Result: Among the three repositories, over 4 million specimen aliquots from more than 150 studies have been banked. This collection represents over 142,000 unique participants across a diverse array of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Dementia, Concussion, Traumatic Brain Injury, Huntington’s Disease, Spinocerebellar Ataxia and other neurodegenerative proteinopathies. More than 600,000 specimen aliquots have been distributed to over 370 investigators, resulting in almost 1,000 publications.Conclusion: NCRAD, BioSEND, and MJFF serve as crucial resources for investigators requiring high‐quality clinical specimens collected and processed in accordance with best practice SOPs. The centralized location at Indiana University provides the opportunity to synergize and align common study objectives to provide shared resources with broader sample diversity, increased statistical power, improved reproducibility, and enhanced opportunities for broad specimen sharing, thereby fostering collaborative research initiatives.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e091931
Open AccessNeurodegeneration Focused Biorepositories: NCRAD, BioSEND, MJFF
Background: Biorepositories play an integral role in the advancement of our understanding of neurodegenerative diseases and improving human health outcomes. Research efforts are accelerated when access to high‐quality clinical specimens is made available from a large, diverse participant group. Indiana University is home to three important neurodegenerative disease‐focused biorepositories including the NIA‐funded National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), the NINDS‐funded Biospecimen Exchange for Neurological Disorders (BioSEND), and the Michael J. Fox Foundation (MJFF) biorepository. Having all three repositories in one location presents a unique opportunity to leverage common protocols and shared resources to provide researchers with access to a wide breadth of specimens, facilitating broad specimen sharing and standardization across studies and repositories.Method: All three repositories provide exceptional data and study coordination, data management, scientific support, and technical resources. Uniform best practice standard operating procedures (SOPs) and materials for collection and processing of samples yield consistently high‐quality specimens across studies from all repositories. Banked specimen types include DNA, RNA, whole blood, plasma, serum, cerebrospinal fluid, urine, stool, brain tissue, peripheral blood mononuclear cells (PBMCs), fibroblasts, and induced pluripotent stem cells (iPSCs). Online catalogs are available for specimen selection along with project management that can assist in the selection and approval of specimens across studies and repositories.Result: Among the three repositories, over 4 million specimen aliquots from more than 150 studies have been banked. This collection represents over 142,000 unique participants across a diverse array of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Dementia, Concussion, Traumatic Brain Injury, Huntington’s Disease, Spinocerebellar Ataxia and other neurodegenerative proteinopathies. More than 600,000 specimen aliquots have been distributed to over 370 investigators, resulting in almost 1,000 publications.Conclusion: NCRAD, BioSEND, and MJFF serve as crucial resources for investigators requiring high‐quality clinical specimens collected and processed in accordance with best practice SOPs. The centralized location at Indiana University provides the opportunity to synergize and align common study objectives to provide shared resources with broader sample diversity, increased statistical power, improved reproducibility, and enhanced opportunities for broad specimen sharing, thereby fostering collaborative research initiatives.
- Open Access
- 21 December 2011
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 369 (1) , 154-159
Structural characterisation of alkyl amine-capped zinc sulphide nanoparticles
- 21 December 2011
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 369 (1) , 154-159
Open AccessStructural characterisation of alkyl amine-capped zinc sulphide nanoparticles